Links to Exploration step
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Vandetanib in Patients With Locally Advanced or Metastatic Medullary Thyroid Cancer: A Randomized, Double-Blind Phase III Trial</title><author><name sortKey="Wells, Samuel A" sort="Wells, Samuel A" uniqKey="Wells S" first="Samuel A." last="Wells">Samuel A. Wells</name><affiliation><nlm:aff id="aff1">Samuel A. Wells Jr, National Cancer Institute, National Institutes of Health, Bethesda, MD; Bruce G. Robinson, Kolling Institute of Medical Research, University of Sydney, Sydney, Australia; Robert F. Gagel, University of Texas MD Anderson Cancer Center, Houston, TX; Henning Dralle, Martin Luther University Halle-Wittenberg, Halle, Germany; James A. Fagin, Memorial Sloan-Kettering Cancer Center, New York, NY; Massimo Santoro, Universita' di Napoli Federico II, Naples, Italy; Eric Baudin and Martin J. Schlumberger, Institut Gustave Roussy, Villejuif, France; Rossella Elisei, University of Pisa, Pisa, Italy; Barbara Jarzab, Maria Sklodowska-Curie Memorial Cancer Center, Gliwice, Poland; James R. Vasselli and Peter Langmuir, AstraZeneca, Wilmington, DE; Jessica Read, AstraZeneca, Macclesfield; and Anderson J. Ryan, University of Oxford, Oxford, United Kingdom.</nlm:aff></affiliation></author><author><name sortKey="Robinson, Bruce G" sort="Robinson, Bruce G" uniqKey="Robinson B" first="Bruce G." last="Robinson">Bruce G. Robinson</name><affiliation><nlm:aff id="aff1">Samuel A. Wells Jr, National Cancer Institute, National Institutes of Health, Bethesda, MD; Bruce G. Robinson, Kolling Institute of Medical Research, University of Sydney, Sydney, Australia; Robert F. Gagel, University of Texas MD Anderson Cancer Center, Houston, TX; Henning Dralle, Martin Luther University Halle-Wittenberg, Halle, Germany; James A. Fagin, Memorial Sloan-Kettering Cancer Center, New York, NY; Massimo Santoro, Universita' di Napoli Federico II, Naples, Italy; Eric Baudin and Martin J. Schlumberger, Institut Gustave Roussy, Villejuif, France; Rossella Elisei, University of Pisa, Pisa, Italy; Barbara Jarzab, Maria Sklodowska-Curie Memorial Cancer Center, Gliwice, Poland; James R. Vasselli and Peter Langmuir, AstraZeneca, Wilmington, DE; Jessica Read, AstraZeneca, Macclesfield; and Anderson J. Ryan, University of Oxford, Oxford, United Kingdom.</nlm:aff></affiliation></author><author><name sortKey="Gagel, Robert F" sort="Gagel, Robert F" uniqKey="Gagel R" first="Robert F." last="Gagel">Robert F. Gagel</name><affiliation><nlm:aff id="aff1">Samuel A. Wells Jr, National Cancer Institute, National Institutes of Health, Bethesda, MD; Bruce G. Robinson, Kolling Institute of Medical Research, University of Sydney, Sydney, Australia; Robert F. Gagel, University of Texas MD Anderson Cancer Center, Houston, TX; Henning Dralle, Martin Luther University Halle-Wittenberg, Halle, Germany; James A. Fagin, Memorial Sloan-Kettering Cancer Center, New York, NY; Massimo Santoro, Universita' di Napoli Federico II, Naples, Italy; Eric Baudin and Martin J. Schlumberger, Institut Gustave Roussy, Villejuif, France; Rossella Elisei, University of Pisa, Pisa, Italy; Barbara Jarzab, Maria Sklodowska-Curie Memorial Cancer Center, Gliwice, Poland; James R. Vasselli and Peter Langmuir, AstraZeneca, Wilmington, DE; Jessica Read, AstraZeneca, Macclesfield; and Anderson J. Ryan, University of Oxford, Oxford, United Kingdom.</nlm:aff></affiliation></author><author><name sortKey="Dralle, Henning" sort="Dralle, Henning" uniqKey="Dralle H" first="Henning" last="Dralle">Henning Dralle</name><affiliation><nlm:aff id="aff1">Samuel A. Wells Jr, National Cancer Institute, National Institutes of Health, Bethesda, MD; Bruce G. Robinson, Kolling Institute of Medical Research, University of Sydney, Sydney, Australia; Robert F. Gagel, University of Texas MD Anderson Cancer Center, Houston, TX; Henning Dralle, Martin Luther University Halle-Wittenberg, Halle, Germany; James A. Fagin, Memorial Sloan-Kettering Cancer Center, New York, NY; Massimo Santoro, Universita' di Napoli Federico II, Naples, Italy; Eric Baudin and Martin J. Schlumberger, Institut Gustave Roussy, Villejuif, France; Rossella Elisei, University of Pisa, Pisa, Italy; Barbara Jarzab, Maria Sklodowska-Curie Memorial Cancer Center, Gliwice, Poland; James R. Vasselli and Peter Langmuir, AstraZeneca, Wilmington, DE; Jessica Read, AstraZeneca, Macclesfield; and Anderson J. Ryan, University of Oxford, Oxford, United Kingdom.</nlm:aff></affiliation></author><author><name sortKey="Fagin, James A" sort="Fagin, James A" uniqKey="Fagin J" first="James A." last="Fagin">James A. Fagin</name><affiliation><nlm:aff id="aff1">Samuel A. Wells Jr, National Cancer Institute, National Institutes of Health, Bethesda, MD; Bruce G. Robinson, Kolling Institute of Medical Research, University of Sydney, Sydney, Australia; Robert F. Gagel, University of Texas MD Anderson Cancer Center, Houston, TX; Henning Dralle, Martin Luther University Halle-Wittenberg, Halle, Germany; James A. Fagin, Memorial Sloan-Kettering Cancer Center, New York, NY; Massimo Santoro, Universita' di Napoli Federico II, Naples, Italy; Eric Baudin and Martin J. Schlumberger, Institut Gustave Roussy, Villejuif, France; Rossella Elisei, University of Pisa, Pisa, Italy; Barbara Jarzab, Maria Sklodowska-Curie Memorial Cancer Center, Gliwice, Poland; James R. Vasselli and Peter Langmuir, AstraZeneca, Wilmington, DE; Jessica Read, AstraZeneca, Macclesfield; and Anderson J. Ryan, University of Oxford, Oxford, United Kingdom.</nlm:aff></affiliation></author><author><name sortKey="Santoro, Massimo" sort="Santoro, Massimo" uniqKey="Santoro M" first="Massimo" last="Santoro">Massimo Santoro</name><affiliation><nlm:aff id="aff1">Samuel A. Wells Jr, National Cancer Institute, National Institutes of Health, Bethesda, MD; Bruce G. Robinson, Kolling Institute of Medical Research, University of Sydney, Sydney, Australia; Robert F. Gagel, University of Texas MD Anderson Cancer Center, Houston, TX; Henning Dralle, Martin Luther University Halle-Wittenberg, Halle, Germany; James A. Fagin, Memorial Sloan-Kettering Cancer Center, New York, NY; Massimo Santoro, Universita' di Napoli Federico II, Naples, Italy; Eric Baudin and Martin J. Schlumberger, Institut Gustave Roussy, Villejuif, France; Rossella Elisei, University of Pisa, Pisa, Italy; Barbara Jarzab, Maria Sklodowska-Curie Memorial Cancer Center, Gliwice, Poland; James R. Vasselli and Peter Langmuir, AstraZeneca, Wilmington, DE; Jessica Read, AstraZeneca, Macclesfield; and Anderson J. Ryan, University of Oxford, Oxford, United Kingdom.</nlm:aff></affiliation></author><author><name sortKey="Baudin, Eric" sort="Baudin, Eric" uniqKey="Baudin E" first="Eric" last="Baudin">Eric Baudin</name><affiliation><nlm:aff id="aff1">Samuel A. Wells Jr, National Cancer Institute, National Institutes of Health, Bethesda, MD; Bruce G. Robinson, Kolling Institute of Medical Research, University of Sydney, Sydney, Australia; Robert F. Gagel, University of Texas MD Anderson Cancer Center, Houston, TX; Henning Dralle, Martin Luther University Halle-Wittenberg, Halle, Germany; James A. Fagin, Memorial Sloan-Kettering Cancer Center, New York, NY; Massimo Santoro, Universita' di Napoli Federico II, Naples, Italy; Eric Baudin and Martin J. Schlumberger, Institut Gustave Roussy, Villejuif, France; Rossella Elisei, University of Pisa, Pisa, Italy; Barbara Jarzab, Maria Sklodowska-Curie Memorial Cancer Center, Gliwice, Poland; James R. Vasselli and Peter Langmuir, AstraZeneca, Wilmington, DE; Jessica Read, AstraZeneca, Macclesfield; and Anderson J. Ryan, University of Oxford, Oxford, United Kingdom.</nlm:aff></affiliation></author><author><name sortKey="Elisei, Rossella" sort="Elisei, Rossella" uniqKey="Elisei R" first="Rossella" last="Elisei">Rossella Elisei</name><affiliation><nlm:aff id="aff1">Samuel A. Wells Jr, National Cancer Institute, National Institutes of Health, Bethesda, MD; Bruce G. Robinson, Kolling Institute of Medical Research, University of Sydney, Sydney, Australia; Robert F. Gagel, University of Texas MD Anderson Cancer Center, Houston, TX; Henning Dralle, Martin Luther University Halle-Wittenberg, Halle, Germany; James A. Fagin, Memorial Sloan-Kettering Cancer Center, New York, NY; Massimo Santoro, Universita' di Napoli Federico II, Naples, Italy; Eric Baudin and Martin J. Schlumberger, Institut Gustave Roussy, Villejuif, France; Rossella Elisei, University of Pisa, Pisa, Italy; Barbara Jarzab, Maria Sklodowska-Curie Memorial Cancer Center, Gliwice, Poland; James R. Vasselli and Peter Langmuir, AstraZeneca, Wilmington, DE; Jessica Read, AstraZeneca, Macclesfield; and Anderson J. Ryan, University of Oxford, Oxford, United Kingdom.</nlm:aff></affiliation></author><author><name sortKey="Jarzab, Barbara" sort="Jarzab, Barbara" uniqKey="Jarzab B" first="Barbara" last="Jarzab">Barbara Jarzab</name><affiliation><nlm:aff id="aff1">Samuel A. Wells Jr, National Cancer Institute, National Institutes of Health, Bethesda, MD; Bruce G. Robinson, Kolling Institute of Medical Research, University of Sydney, Sydney, Australia; Robert F. Gagel, University of Texas MD Anderson Cancer Center, Houston, TX; Henning Dralle, Martin Luther University Halle-Wittenberg, Halle, Germany; James A. Fagin, Memorial Sloan-Kettering Cancer Center, New York, NY; Massimo Santoro, Universita' di Napoli Federico II, Naples, Italy; Eric Baudin and Martin J. Schlumberger, Institut Gustave Roussy, Villejuif, France; Rossella Elisei, University of Pisa, Pisa, Italy; Barbara Jarzab, Maria Sklodowska-Curie Memorial Cancer Center, Gliwice, Poland; James R. Vasselli and Peter Langmuir, AstraZeneca, Wilmington, DE; Jessica Read, AstraZeneca, Macclesfield; and Anderson J. Ryan, University of Oxford, Oxford, United Kingdom.</nlm:aff></affiliation></author><author><name sortKey="Vasselli, James R" sort="Vasselli, James R" uniqKey="Vasselli J" first="James R." last="Vasselli">James R. Vasselli</name><affiliation><nlm:aff id="aff1">Samuel A. Wells Jr, National Cancer Institute, National Institutes of Health, Bethesda, MD; Bruce G. Robinson, Kolling Institute of Medical Research, University of Sydney, Sydney, Australia; Robert F. Gagel, University of Texas MD Anderson Cancer Center, Houston, TX; Henning Dralle, Martin Luther University Halle-Wittenberg, Halle, Germany; James A. Fagin, Memorial Sloan-Kettering Cancer Center, New York, NY; Massimo Santoro, Universita' di Napoli Federico II, Naples, Italy; Eric Baudin and Martin J. Schlumberger, Institut Gustave Roussy, Villejuif, France; Rossella Elisei, University of Pisa, Pisa, Italy; Barbara Jarzab, Maria Sklodowska-Curie Memorial Cancer Center, Gliwice, Poland; James R. Vasselli and Peter Langmuir, AstraZeneca, Wilmington, DE; Jessica Read, AstraZeneca, Macclesfield; and Anderson J. Ryan, University of Oxford, Oxford, United Kingdom.</nlm:aff></affiliation></author><author><name sortKey="Read, Jessica" sort="Read, Jessica" uniqKey="Read J" first="Jessica" last="Read">Jessica Read</name><affiliation><nlm:aff id="aff1">Samuel A. Wells Jr, National Cancer Institute, National Institutes of Health, Bethesda, MD; Bruce G. Robinson, Kolling Institute of Medical Research, University of Sydney, Sydney, Australia; Robert F. Gagel, University of Texas MD Anderson Cancer Center, Houston, TX; Henning Dralle, Martin Luther University Halle-Wittenberg, Halle, Germany; James A. Fagin, Memorial Sloan-Kettering Cancer Center, New York, NY; Massimo Santoro, Universita' di Napoli Federico II, Naples, Italy; Eric Baudin and Martin J. Schlumberger, Institut Gustave Roussy, Villejuif, France; Rossella Elisei, University of Pisa, Pisa, Italy; Barbara Jarzab, Maria Sklodowska-Curie Memorial Cancer Center, Gliwice, Poland; James R. Vasselli and Peter Langmuir, AstraZeneca, Wilmington, DE; Jessica Read, AstraZeneca, Macclesfield; and Anderson J. Ryan, University of Oxford, Oxford, United Kingdom.</nlm:aff></affiliation></author><author><name sortKey="Langmuir, Peter" sort="Langmuir, Peter" uniqKey="Langmuir P" first="Peter" last="Langmuir">Peter Langmuir</name><affiliation><nlm:aff id="aff1">Samuel A. Wells Jr, National Cancer Institute, National Institutes of Health, Bethesda, MD; Bruce G. Robinson, Kolling Institute of Medical Research, University of Sydney, Sydney, Australia; Robert F. Gagel, University of Texas MD Anderson Cancer Center, Houston, TX; Henning Dralle, Martin Luther University Halle-Wittenberg, Halle, Germany; James A. Fagin, Memorial Sloan-Kettering Cancer Center, New York, NY; Massimo Santoro, Universita' di Napoli Federico II, Naples, Italy; Eric Baudin and Martin J. Schlumberger, Institut Gustave Roussy, Villejuif, France; Rossella Elisei, University of Pisa, Pisa, Italy; Barbara Jarzab, Maria Sklodowska-Curie Memorial Cancer Center, Gliwice, Poland; James R. Vasselli and Peter Langmuir, AstraZeneca, Wilmington, DE; Jessica Read, AstraZeneca, Macclesfield; and Anderson J. Ryan, University of Oxford, Oxford, United Kingdom.</nlm:aff></affiliation></author><author><name sortKey="Ryan, Anderson J" sort="Ryan, Anderson J" uniqKey="Ryan A" first="Anderson J." last="Ryan">Anderson J. Ryan</name><affiliation><nlm:aff id="aff1">Samuel A. Wells Jr, National Cancer Institute, National Institutes of Health, Bethesda, MD; Bruce G. Robinson, Kolling Institute of Medical Research, University of Sydney, Sydney, Australia; Robert F. Gagel, University of Texas MD Anderson Cancer Center, Houston, TX; Henning Dralle, Martin Luther University Halle-Wittenberg, Halle, Germany; James A. Fagin, Memorial Sloan-Kettering Cancer Center, New York, NY; Massimo Santoro, Universita' di Napoli Federico II, Naples, Italy; Eric Baudin and Martin J. Schlumberger, Institut Gustave Roussy, Villejuif, France; Rossella Elisei, University of Pisa, Pisa, Italy; Barbara Jarzab, Maria Sklodowska-Curie Memorial Cancer Center, Gliwice, Poland; James R. Vasselli and Peter Langmuir, AstraZeneca, Wilmington, DE; Jessica Read, AstraZeneca, Macclesfield; and Anderson J. Ryan, University of Oxford, Oxford, United Kingdom.</nlm:aff></affiliation></author><author><name sortKey="Schlumberger, Martin J" sort="Schlumberger, Martin J" uniqKey="Schlumberger M" first="Martin J." last="Schlumberger">Martin J. Schlumberger</name><affiliation><nlm:aff id="aff1">Samuel A. Wells Jr, National Cancer Institute, National Institutes of Health, Bethesda, MD; Bruce G. Robinson, Kolling Institute of Medical Research, University of Sydney, Sydney, Australia; Robert F. Gagel, University of Texas MD Anderson Cancer Center, Houston, TX; Henning Dralle, Martin Luther University Halle-Wittenberg, Halle, Germany; James A. Fagin, Memorial Sloan-Kettering Cancer Center, New York, NY; Massimo Santoro, Universita' di Napoli Federico II, Naples, Italy; Eric Baudin and Martin J. Schlumberger, Institut Gustave Roussy, Villejuif, France; Rossella Elisei, University of Pisa, Pisa, Italy; Barbara Jarzab, Maria Sklodowska-Curie Memorial Cancer Center, Gliwice, Poland; James R. Vasselli and Peter Langmuir, AstraZeneca, Wilmington, DE; Jessica Read, AstraZeneca, Macclesfield; and Anderson J. Ryan, University of Oxford, Oxford, United Kingdom.</nlm:aff></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">22025146</idno><idno type="pmc">3675689</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3675689</idno><idno type="RBID">PMC:3675689</idno><idno type="doi">10.1200/JCO.2011.35.5040</idno><date when="2011">2011</date><idno type="wicri:Area/Pmc/Corpus">001947</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">001947</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Vandetanib in Patients With Locally Advanced or Metastatic Medullary Thyroid Cancer: A Randomized, Double-Blind Phase III Trial</title><author><name sortKey="Wells, Samuel A" sort="Wells, Samuel A" uniqKey="Wells S" first="Samuel A." last="Wells">Samuel A. Wells</name><affiliation><nlm:aff id="aff1">Samuel A. Wells Jr, National Cancer Institute, National Institutes of Health, Bethesda, MD; Bruce G. Robinson, Kolling Institute of Medical Research, University of Sydney, Sydney, Australia; Robert F. Gagel, University of Texas MD Anderson Cancer Center, Houston, TX; Henning Dralle, Martin Luther University Halle-Wittenberg, Halle, Germany; James A. Fagin, Memorial Sloan-Kettering Cancer Center, New York, NY; Massimo Santoro, Universita' di Napoli Federico II, Naples, Italy; Eric Baudin and Martin J. Schlumberger, Institut Gustave Roussy, Villejuif, France; Rossella Elisei, University of Pisa, Pisa, Italy; Barbara Jarzab, Maria Sklodowska-Curie Memorial Cancer Center, Gliwice, Poland; James R. Vasselli and Peter Langmuir, AstraZeneca, Wilmington, DE; Jessica Read, AstraZeneca, Macclesfield; and Anderson J. Ryan, University of Oxford, Oxford, United Kingdom.</nlm:aff></affiliation></author><author><name sortKey="Robinson, Bruce G" sort="Robinson, Bruce G" uniqKey="Robinson B" first="Bruce G." last="Robinson">Bruce G. Robinson</name><affiliation><nlm:aff id="aff1">Samuel A. Wells Jr, National Cancer Institute, National Institutes of Health, Bethesda, MD; Bruce G. Robinson, Kolling Institute of Medical Research, University of Sydney, Sydney, Australia; Robert F. Gagel, University of Texas MD Anderson Cancer Center, Houston, TX; Henning Dralle, Martin Luther University Halle-Wittenberg, Halle, Germany; James A. Fagin, Memorial Sloan-Kettering Cancer Center, New York, NY; Massimo Santoro, Universita' di Napoli Federico II, Naples, Italy; Eric Baudin and Martin J. Schlumberger, Institut Gustave Roussy, Villejuif, France; Rossella Elisei, University of Pisa, Pisa, Italy; Barbara Jarzab, Maria Sklodowska-Curie Memorial Cancer Center, Gliwice, Poland; James R. Vasselli and Peter Langmuir, AstraZeneca, Wilmington, DE; Jessica Read, AstraZeneca, Macclesfield; and Anderson J. Ryan, University of Oxford, Oxford, United Kingdom.</nlm:aff></affiliation></author><author><name sortKey="Gagel, Robert F" sort="Gagel, Robert F" uniqKey="Gagel R" first="Robert F." last="Gagel">Robert F. Gagel</name><affiliation><nlm:aff id="aff1">Samuel A. Wells Jr, National Cancer Institute, National Institutes of Health, Bethesda, MD; Bruce G. Robinson, Kolling Institute of Medical Research, University of Sydney, Sydney, Australia; Robert F. Gagel, University of Texas MD Anderson Cancer Center, Houston, TX; Henning Dralle, Martin Luther University Halle-Wittenberg, Halle, Germany; James A. Fagin, Memorial Sloan-Kettering Cancer Center, New York, NY; Massimo Santoro, Universita' di Napoli Federico II, Naples, Italy; Eric Baudin and Martin J. Schlumberger, Institut Gustave Roussy, Villejuif, France; Rossella Elisei, University of Pisa, Pisa, Italy; Barbara Jarzab, Maria Sklodowska-Curie Memorial Cancer Center, Gliwice, Poland; James R. Vasselli and Peter Langmuir, AstraZeneca, Wilmington, DE; Jessica Read, AstraZeneca, Macclesfield; and Anderson J. Ryan, University of Oxford, Oxford, United Kingdom.</nlm:aff></affiliation></author><author><name sortKey="Dralle, Henning" sort="Dralle, Henning" uniqKey="Dralle H" first="Henning" last="Dralle">Henning Dralle</name><affiliation><nlm:aff id="aff1">Samuel A. Wells Jr, National Cancer Institute, National Institutes of Health, Bethesda, MD; Bruce G. Robinson, Kolling Institute of Medical Research, University of Sydney, Sydney, Australia; Robert F. Gagel, University of Texas MD Anderson Cancer Center, Houston, TX; Henning Dralle, Martin Luther University Halle-Wittenberg, Halle, Germany; James A. Fagin, Memorial Sloan-Kettering Cancer Center, New York, NY; Massimo Santoro, Universita' di Napoli Federico II, Naples, Italy; Eric Baudin and Martin J. Schlumberger, Institut Gustave Roussy, Villejuif, France; Rossella Elisei, University of Pisa, Pisa, Italy; Barbara Jarzab, Maria Sklodowska-Curie Memorial Cancer Center, Gliwice, Poland; James R. Vasselli and Peter Langmuir, AstraZeneca, Wilmington, DE; Jessica Read, AstraZeneca, Macclesfield; and Anderson J. Ryan, University of Oxford, Oxford, United Kingdom.</nlm:aff></affiliation></author><author><name sortKey="Fagin, James A" sort="Fagin, James A" uniqKey="Fagin J" first="James A." last="Fagin">James A. Fagin</name><affiliation><nlm:aff id="aff1">Samuel A. Wells Jr, National Cancer Institute, National Institutes of Health, Bethesda, MD; Bruce G. Robinson, Kolling Institute of Medical Research, University of Sydney, Sydney, Australia; Robert F. Gagel, University of Texas MD Anderson Cancer Center, Houston, TX; Henning Dralle, Martin Luther University Halle-Wittenberg, Halle, Germany; James A. Fagin, Memorial Sloan-Kettering Cancer Center, New York, NY; Massimo Santoro, Universita' di Napoli Federico II, Naples, Italy; Eric Baudin and Martin J. Schlumberger, Institut Gustave Roussy, Villejuif, France; Rossella Elisei, University of Pisa, Pisa, Italy; Barbara Jarzab, Maria Sklodowska-Curie Memorial Cancer Center, Gliwice, Poland; James R. Vasselli and Peter Langmuir, AstraZeneca, Wilmington, DE; Jessica Read, AstraZeneca, Macclesfield; and Anderson J. Ryan, University of Oxford, Oxford, United Kingdom.</nlm:aff></affiliation></author><author><name sortKey="Santoro, Massimo" sort="Santoro, Massimo" uniqKey="Santoro M" first="Massimo" last="Santoro">Massimo Santoro</name><affiliation><nlm:aff id="aff1">Samuel A. Wells Jr, National Cancer Institute, National Institutes of Health, Bethesda, MD; Bruce G. Robinson, Kolling Institute of Medical Research, University of Sydney, Sydney, Australia; Robert F. Gagel, University of Texas MD Anderson Cancer Center, Houston, TX; Henning Dralle, Martin Luther University Halle-Wittenberg, Halle, Germany; James A. Fagin, Memorial Sloan-Kettering Cancer Center, New York, NY; Massimo Santoro, Universita' di Napoli Federico II, Naples, Italy; Eric Baudin and Martin J. Schlumberger, Institut Gustave Roussy, Villejuif, France; Rossella Elisei, University of Pisa, Pisa, Italy; Barbara Jarzab, Maria Sklodowska-Curie Memorial Cancer Center, Gliwice, Poland; James R. Vasselli and Peter Langmuir, AstraZeneca, Wilmington, DE; Jessica Read, AstraZeneca, Macclesfield; and Anderson J. Ryan, University of Oxford, Oxford, United Kingdom.</nlm:aff></affiliation></author><author><name sortKey="Baudin, Eric" sort="Baudin, Eric" uniqKey="Baudin E" first="Eric" last="Baudin">Eric Baudin</name><affiliation><nlm:aff id="aff1">Samuel A. Wells Jr, National Cancer Institute, National Institutes of Health, Bethesda, MD; Bruce G. Robinson, Kolling Institute of Medical Research, University of Sydney, Sydney, Australia; Robert F. Gagel, University of Texas MD Anderson Cancer Center, Houston, TX; Henning Dralle, Martin Luther University Halle-Wittenberg, Halle, Germany; James A. Fagin, Memorial Sloan-Kettering Cancer Center, New York, NY; Massimo Santoro, Universita' di Napoli Federico II, Naples, Italy; Eric Baudin and Martin J. Schlumberger, Institut Gustave Roussy, Villejuif, France; Rossella Elisei, University of Pisa, Pisa, Italy; Barbara Jarzab, Maria Sklodowska-Curie Memorial Cancer Center, Gliwice, Poland; James R. Vasselli and Peter Langmuir, AstraZeneca, Wilmington, DE; Jessica Read, AstraZeneca, Macclesfield; and Anderson J. Ryan, University of Oxford, Oxford, United Kingdom.</nlm:aff></affiliation></author><author><name sortKey="Elisei, Rossella" sort="Elisei, Rossella" uniqKey="Elisei R" first="Rossella" last="Elisei">Rossella Elisei</name><affiliation><nlm:aff id="aff1">Samuel A. Wells Jr, National Cancer Institute, National Institutes of Health, Bethesda, MD; Bruce G. Robinson, Kolling Institute of Medical Research, University of Sydney, Sydney, Australia; Robert F. Gagel, University of Texas MD Anderson Cancer Center, Houston, TX; Henning Dralle, Martin Luther University Halle-Wittenberg, Halle, Germany; James A. Fagin, Memorial Sloan-Kettering Cancer Center, New York, NY; Massimo Santoro, Universita' di Napoli Federico II, Naples, Italy; Eric Baudin and Martin J. Schlumberger, Institut Gustave Roussy, Villejuif, France; Rossella Elisei, University of Pisa, Pisa, Italy; Barbara Jarzab, Maria Sklodowska-Curie Memorial Cancer Center, Gliwice, Poland; James R. Vasselli and Peter Langmuir, AstraZeneca, Wilmington, DE; Jessica Read, AstraZeneca, Macclesfield; and Anderson J. Ryan, University of Oxford, Oxford, United Kingdom.</nlm:aff></affiliation></author><author><name sortKey="Jarzab, Barbara" sort="Jarzab, Barbara" uniqKey="Jarzab B" first="Barbara" last="Jarzab">Barbara Jarzab</name><affiliation><nlm:aff id="aff1">Samuel A. Wells Jr, National Cancer Institute, National Institutes of Health, Bethesda, MD; Bruce G. Robinson, Kolling Institute of Medical Research, University of Sydney, Sydney, Australia; Robert F. Gagel, University of Texas MD Anderson Cancer Center, Houston, TX; Henning Dralle, Martin Luther University Halle-Wittenberg, Halle, Germany; James A. Fagin, Memorial Sloan-Kettering Cancer Center, New York, NY; Massimo Santoro, Universita' di Napoli Federico II, Naples, Italy; Eric Baudin and Martin J. Schlumberger, Institut Gustave Roussy, Villejuif, France; Rossella Elisei, University of Pisa, Pisa, Italy; Barbara Jarzab, Maria Sklodowska-Curie Memorial Cancer Center, Gliwice, Poland; James R. Vasselli and Peter Langmuir, AstraZeneca, Wilmington, DE; Jessica Read, AstraZeneca, Macclesfield; and Anderson J. Ryan, University of Oxford, Oxford, United Kingdom.</nlm:aff></affiliation></author><author><name sortKey="Vasselli, James R" sort="Vasselli, James R" uniqKey="Vasselli J" first="James R." last="Vasselli">James R. Vasselli</name><affiliation><nlm:aff id="aff1">Samuel A. Wells Jr, National Cancer Institute, National Institutes of Health, Bethesda, MD; Bruce G. Robinson, Kolling Institute of Medical Research, University of Sydney, Sydney, Australia; Robert F. Gagel, University of Texas MD Anderson Cancer Center, Houston, TX; Henning Dralle, Martin Luther University Halle-Wittenberg, Halle, Germany; James A. Fagin, Memorial Sloan-Kettering Cancer Center, New York, NY; Massimo Santoro, Universita' di Napoli Federico II, Naples, Italy; Eric Baudin and Martin J. Schlumberger, Institut Gustave Roussy, Villejuif, France; Rossella Elisei, University of Pisa, Pisa, Italy; Barbara Jarzab, Maria Sklodowska-Curie Memorial Cancer Center, Gliwice, Poland; James R. Vasselli and Peter Langmuir, AstraZeneca, Wilmington, DE; Jessica Read, AstraZeneca, Macclesfield; and Anderson J. Ryan, University of Oxford, Oxford, United Kingdom.</nlm:aff></affiliation></author><author><name sortKey="Read, Jessica" sort="Read, Jessica" uniqKey="Read J" first="Jessica" last="Read">Jessica Read</name><affiliation><nlm:aff id="aff1">Samuel A. Wells Jr, National Cancer Institute, National Institutes of Health, Bethesda, MD; Bruce G. Robinson, Kolling Institute of Medical Research, University of Sydney, Sydney, Australia; Robert F. Gagel, University of Texas MD Anderson Cancer Center, Houston, TX; Henning Dralle, Martin Luther University Halle-Wittenberg, Halle, Germany; James A. Fagin, Memorial Sloan-Kettering Cancer Center, New York, NY; Massimo Santoro, Universita' di Napoli Federico II, Naples, Italy; Eric Baudin and Martin J. Schlumberger, Institut Gustave Roussy, Villejuif, France; Rossella Elisei, University of Pisa, Pisa, Italy; Barbara Jarzab, Maria Sklodowska-Curie Memorial Cancer Center, Gliwice, Poland; James R. Vasselli and Peter Langmuir, AstraZeneca, Wilmington, DE; Jessica Read, AstraZeneca, Macclesfield; and Anderson J. Ryan, University of Oxford, Oxford, United Kingdom.</nlm:aff></affiliation></author><author><name sortKey="Langmuir, Peter" sort="Langmuir, Peter" uniqKey="Langmuir P" first="Peter" last="Langmuir">Peter Langmuir</name><affiliation><nlm:aff id="aff1">Samuel A. Wells Jr, National Cancer Institute, National Institutes of Health, Bethesda, MD; Bruce G. Robinson, Kolling Institute of Medical Research, University of Sydney, Sydney, Australia; Robert F. Gagel, University of Texas MD Anderson Cancer Center, Houston, TX; Henning Dralle, Martin Luther University Halle-Wittenberg, Halle, Germany; James A. Fagin, Memorial Sloan-Kettering Cancer Center, New York, NY; Massimo Santoro, Universita' di Napoli Federico II, Naples, Italy; Eric Baudin and Martin J. Schlumberger, Institut Gustave Roussy, Villejuif, France; Rossella Elisei, University of Pisa, Pisa, Italy; Barbara Jarzab, Maria Sklodowska-Curie Memorial Cancer Center, Gliwice, Poland; James R. Vasselli and Peter Langmuir, AstraZeneca, Wilmington, DE; Jessica Read, AstraZeneca, Macclesfield; and Anderson J. Ryan, University of Oxford, Oxford, United Kingdom.</nlm:aff></affiliation></author><author><name sortKey="Ryan, Anderson J" sort="Ryan, Anderson J" uniqKey="Ryan A" first="Anderson J." last="Ryan">Anderson J. Ryan</name><affiliation><nlm:aff id="aff1">Samuel A. Wells Jr, National Cancer Institute, National Institutes of Health, Bethesda, MD; Bruce G. Robinson, Kolling Institute of Medical Research, University of Sydney, Sydney, Australia; Robert F. Gagel, University of Texas MD Anderson Cancer Center, Houston, TX; Henning Dralle, Martin Luther University Halle-Wittenberg, Halle, Germany; James A. Fagin, Memorial Sloan-Kettering Cancer Center, New York, NY; Massimo Santoro, Universita' di Napoli Federico II, Naples, Italy; Eric Baudin and Martin J. Schlumberger, Institut Gustave Roussy, Villejuif, France; Rossella Elisei, University of Pisa, Pisa, Italy; Barbara Jarzab, Maria Sklodowska-Curie Memorial Cancer Center, Gliwice, Poland; James R. Vasselli and Peter Langmuir, AstraZeneca, Wilmington, DE; Jessica Read, AstraZeneca, Macclesfield; and Anderson J. Ryan, University of Oxford, Oxford, United Kingdom.</nlm:aff></affiliation></author><author><name sortKey="Schlumberger, Martin J" sort="Schlumberger, Martin J" uniqKey="Schlumberger M" first="Martin J." last="Schlumberger">Martin J. Schlumberger</name><affiliation><nlm:aff id="aff1">Samuel A. Wells Jr, National Cancer Institute, National Institutes of Health, Bethesda, MD; Bruce G. Robinson, Kolling Institute of Medical Research, University of Sydney, Sydney, Australia; Robert F. Gagel, University of Texas MD Anderson Cancer Center, Houston, TX; Henning Dralle, Martin Luther University Halle-Wittenberg, Halle, Germany; James A. Fagin, Memorial Sloan-Kettering Cancer Center, New York, NY; Massimo Santoro, Universita' di Napoli Federico II, Naples, Italy; Eric Baudin and Martin J. Schlumberger, Institut Gustave Roussy, Villejuif, France; Rossella Elisei, University of Pisa, Pisa, Italy; Barbara Jarzab, Maria Sklodowska-Curie Memorial Cancer Center, Gliwice, Poland; James R. Vasselli and Peter Langmuir, AstraZeneca, Wilmington, DE; Jessica Read, AstraZeneca, Macclesfield; and Anderson J. Ryan, University of Oxford, Oxford, United Kingdom.</nlm:aff></affiliation></author></analytic><series><title level="j">Journal of Clinical Oncology</title><idno type="ISSN">0732-183X</idno><idno type="eISSN">1527-7755</idno><imprint><date when="2011">2011</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><sec><title>Purpose</title><p>There is no effective therapy for patients with advanced medullary thyroid carcinoma (MTC). Vandetanib, a once-daily oral inhibitor of RET kinase, vascular endothelial growth factor receptor, and epidermal growth factor receptor signaling, has previously shown antitumor activity in a phase II study of patients with advanced hereditary MTC.</p></sec><sec><title>Patients and Methods</title><p>Patients with advanced MTC were randomly assigned in a 2:1 ratio to receive vandetanib 300 mg/d or placebo. On objective disease progression, patients could elect to receive open-label vandetanib. The primary end point was progression-free survival (PFS), determined by independent central Response Evaluation Criteria in Solid Tumors (RECIST) assessments.</p></sec><sec><title>Results</title><p>Between December 2006 and November 2007, 331 patients (mean age, 52 years; 90% sporadic; 95% metastatic) were randomly assigned to receive vandetanib (231) or placebo (100). At data cutoff (July 2009; median follow-up, 24 months), 37% of patients had progressed and 15% had died. The study met its primary objective of PFS prolongation with vandetanib versus placebo (hazard ratio [HR], 0.46; 95% CI, 0.31 to 0.69; <italic>P</italic> < .001). Statistically significant advantages for vandetanib were also seen for objective response rate (<italic>P</italic> < .001), disease control rate (<italic>P</italic> = .001), and biochemical response (<italic>P</italic> < .001). Overall survival data were immature at data cutoff (HR, 0.89; 95% CI, 0.48 to 1.65). A final survival analysis will take place when 50% of the patients have died. Common adverse events (any grade) occurred more frequently with vandetanib compared with placebo, including diarrhea (56% <italic>v</italic> 26%), rash (45% <italic>v</italic> 11%), nausea (33% <italic>v</italic> 16%), hypertension (32% <italic>v</italic> 5%), and headache (26% <italic>v</italic> 9%).</p></sec><sec><title>Conclusion</title><p>Vandetanib demonstrated therapeutic efficacy in a phase III trial of patients with advanced MTC (ClinicalTrials.gov NCT00410761).</p></sec></div></front></TEI><pmc article-type="research-article"><pmc-comment>The publisher of this article does not allow downloading of the full text in XML form.</pmc-comment>
<front><journal-meta><journal-id journal-id-type="nlm-ta">J Clin Oncol</journal-id><journal-id journal-id-type="iso-abbrev">J. Clin. Oncol</journal-id><journal-id journal-id-type="hwp">jco</journal-id><journal-id journal-id-type="pmc">jco</journal-id><journal-id journal-id-type="publisher-id">JCO</journal-id><journal-title-group><journal-title>Journal of Clinical Oncology</journal-title></journal-title-group><issn pub-type="ppub">0732-183X</issn><issn pub-type="epub">1527-7755</issn><publisher><publisher-name>American Society of Clinical Oncology</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">22025146</article-id><article-id pub-id-type="pmc">3675689</article-id><article-id pub-id-type="publisher-id">55040</article-id><article-id pub-id-type="doi">10.1200/JCO.2011.35.5040</article-id><article-categories><subj-group subj-group-type="hwp-journal-coll"><subject>Endo7</subject><subject>Hnc7</subject></subj-group><subj-group subj-group-type="heading"><subject>Original Reports</subject><subj-group><subject>Head and Neck Cancer</subject></subj-group></subj-group></article-categories><title-group><article-title>Vandetanib in Patients With Locally Advanced or Metastatic Medullary Thyroid Cancer: A Randomized, Double-Blind Phase III Trial</article-title><alt-title alt-title-type="short">Vandetanib for Advanced Medullary Thyroid Cancer</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Wells</surname><given-names>Samuel A.</given-names><suffix>Jr</suffix></name><xref ref-type="aff" rid="aff1"></xref><xref ref-type="corresp" rid="cor1"></xref></contrib><contrib contrib-type="author"><name><surname>Robinson</surname><given-names>Bruce G.</given-names></name><xref ref-type="aff" rid="aff1"></xref></contrib><contrib contrib-type="author"><name><surname>Gagel</surname><given-names>Robert F.</given-names></name><xref ref-type="aff" rid="aff1"></xref></contrib><contrib contrib-type="author"><name><surname>Dralle</surname><given-names>Henning</given-names></name><xref ref-type="aff" rid="aff1"></xref></contrib><contrib contrib-type="author"><name><surname>Fagin</surname><given-names>James A.</given-names></name><xref ref-type="aff" rid="aff1"></xref></contrib><contrib contrib-type="author"><name><surname>Santoro</surname><given-names>Massimo</given-names></name><xref ref-type="aff" rid="aff1"></xref></contrib><contrib contrib-type="author"><name><surname>Baudin</surname><given-names>Eric</given-names></name><xref ref-type="aff" rid="aff1"></xref></contrib><contrib contrib-type="author"><name><surname>Elisei</surname><given-names>Rossella</given-names></name><xref ref-type="aff" rid="aff1"></xref></contrib><contrib contrib-type="author"><name><surname>Jarzab</surname><given-names>Barbara</given-names></name><xref ref-type="aff" rid="aff1"></xref></contrib><contrib contrib-type="author"><name><surname>Vasselli</surname><given-names>James R.</given-names></name><xref ref-type="aff" rid="aff1"></xref></contrib><contrib contrib-type="author"><name><surname>Read</surname><given-names>Jessica</given-names></name><xref ref-type="aff" rid="aff1"></xref></contrib><contrib contrib-type="author"><name><surname>Langmuir</surname><given-names>Peter</given-names></name><xref ref-type="aff" rid="aff1"></xref></contrib><contrib contrib-type="author"><name><surname>Ryan</surname><given-names>Anderson J.</given-names></name><xref ref-type="aff" rid="aff1"></xref></contrib><contrib contrib-type="author"><name><surname>Schlumberger</surname><given-names>Martin J.</given-names></name><xref ref-type="aff" rid="aff1"></xref></contrib><aff id="aff1">Samuel A. Wells Jr, National Cancer Institute, National Institutes of Health, Bethesda, MD; Bruce G. Robinson, Kolling Institute of Medical Research, University of Sydney, Sydney, Australia; Robert F. Gagel, University of Texas MD Anderson Cancer Center, Houston, TX; Henning Dralle, Martin Luther University Halle-Wittenberg, Halle, Germany; James A. Fagin, Memorial Sloan-Kettering Cancer Center, New York, NY; Massimo Santoro, Universita' di Napoli Federico II, Naples, Italy; Eric Baudin and Martin J. Schlumberger, Institut Gustave Roussy, Villejuif, France; Rossella Elisei, University of Pisa, Pisa, Italy; Barbara Jarzab, Maria Sklodowska-Curie Memorial Cancer Center, Gliwice, Poland; James R. Vasselli and Peter Langmuir, AstraZeneca, Wilmington, DE; Jessica Read, AstraZeneca, Macclesfield; and Anderson J. Ryan, University of Oxford, Oxford, United Kingdom.</aff></contrib-group><author-notes><corresp id="cor1">Corresponding author: Samuel A. Wells Jr, MD, Medical Oncology Branch, National Cancer Institute, National Institutes of Health, Building 10, Room 13N-240E MSC 1206, 9000 Rockville Pike, Bethesda, MD 20892; e-mail: <email>wellss@mail.nih.gov</email>.</corresp></author-notes><pub-date pub-type="ppub"><day>10</day><month>1</month><year>2012</year></pub-date><pub-date pub-type="epub"><day>24</day><month>10</month><year>2011</year></pub-date><pub-date pub-type="pmc-release"><day>10</day><month>1</month><year>2013</year></pub-date><pmc-comment> PMC Release delay is 12 months and 0 days and was based on the
<volume>30</volume><issue>2</issue><fpage>134</fpage><lpage>141</lpage><history><date date-type="received"><day>18</day><month>2</month><year>2011</year></date><date date-type="accepted"><day>11</day><month>7</month><year>2011</year></date></history><permissions><copyright-statement>© 2011 by American Society of Clinical Oncology</copyright-statement><copyright-year>2011</copyright-year></permissions><self-uri xlink:title="pdf" xlink:type="simple" xlink:href="zlj00212000134.pdf"></self-uri><abstract><sec><title>Purpose</title><p>There is no effective therapy for patients with advanced medullary thyroid carcinoma (MTC). Vandetanib, a once-daily oral inhibitor of RET kinase, vascular endothelial growth factor receptor, and epidermal growth factor receptor signaling, has previously shown antitumor activity in a phase II study of patients with advanced hereditary MTC.</p></sec><sec><title>Patients and Methods</title><p>Patients with advanced MTC were randomly assigned in a 2:1 ratio to receive vandetanib 300 mg/d or placebo. On objective disease progression, patients could elect to receive open-label vandetanib. The primary end point was progression-free survival (PFS), determined by independent central Response Evaluation Criteria in Solid Tumors (RECIST) assessments.</p></sec><sec><title>Results</title><p>Between December 2006 and November 2007, 331 patients (mean age, 52 years; 90% sporadic; 95% metastatic) were randomly assigned to receive vandetanib (231) or placebo (100). At data cutoff (July 2009; median follow-up, 24 months), 37% of patients had progressed and 15% had died. The study met its primary objective of PFS prolongation with vandetanib versus placebo (hazard ratio [HR], 0.46; 95% CI, 0.31 to 0.69; <italic>P</italic> < .001). Statistically significant advantages for vandetanib were also seen for objective response rate (<italic>P</italic> < .001), disease control rate (<italic>P</italic> = .001), and biochemical response (<italic>P</italic> < .001). Overall survival data were immature at data cutoff (HR, 0.89; 95% CI, 0.48 to 1.65). A final survival analysis will take place when 50% of the patients have died. Common adverse events (any grade) occurred more frequently with vandetanib compared with placebo, including diarrhea (56% <italic>v</italic> 26%), rash (45% <italic>v</italic> 11%), nausea (33% <italic>v</italic> 16%), hypertension (32% <italic>v</italic> 5%), and headache (26% <italic>v</italic> 9%).</p></sec><sec><title>Conclusion</title><p>Vandetanib demonstrated therapeutic efficacy in a phase III trial of patients with advanced MTC (ClinicalTrials.gov NCT00410761).</p></sec></abstract></article-meta></front></pmc></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Pmc/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001947 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd -nk 001947 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Pmc
|étape= Corpus
|type= RBID
|clé=
|texte=
}}
| This area was generated with Dilib version V0.6.33. |  |